[ { "@id": "http://purl.org/np/RAZW8rLrF4eNXyUjFi5-p_RCY65f2Uq13458Nj2spZNgQ#Head", "@graph": [ { "@id": "http://purl.org/np/RAZW8rLrF4eNXyUjFi5-p_RCY65f2Uq13458Nj2spZNgQ", "http://www.nanopub.org/nschema#hasAssertion": [ { "@id": "http://purl.org/np/RAZW8rLrF4eNXyUjFi5-p_RCY65f2Uq13458Nj2spZNgQ#assertion" } ], "http://www.nanopub.org/nschema#hasProvenance": [ { "@id": "http://purl.org/np/RAZW8rLrF4eNXyUjFi5-p_RCY65f2Uq13458Nj2spZNgQ#provenance" } ], "http://www.nanopub.org/nschema#hasPublicationInfo": [ { "@id": "http://purl.org/np/RAZW8rLrF4eNXyUjFi5-p_RCY65f2Uq13458Nj2spZNgQ#pubinfo" } ], "@type": [ "http://www.nanopub.org/nschema#Nanopublication" ] } ] }, { "@id": "http://purl.org/np/RAZW8rLrF4eNXyUjFi5-p_RCY65f2Uq13458Nj2spZNgQ#assertion", "@graph": [ { "@id": "http://purl.obolibrary.org/obo/SYMP_0000271", "https://schema.org/possibleTreatment": [ { "@id": "http://purl.org/np/RAZW8rLrF4eNXyUjFi5-p_RCY65f2Uq13458Nj2spZNgQ#medtherapy" } ] }, { "@id": "http://purl.org/np/RAZW8rLrF4eNXyUjFi5-p_RCY65f2Uq13458Nj2spZNgQ#medtherapy", "http://www.w3.org/ns/prov#wasDerivedFrom": [ { "@id": "http://purl.org/np/RAZW8rLrF4eNXyUjFi5-p_RCY65f2Uq13458Nj2spZNgQ#quote" } ], "https://schema.org/drug": [ { "@id": "http://identifiers.org/drugbank/DB01080" } ], "https://schema.org/targetPopulation": [ { "@id": "http://purl.org/np/RAZW8rLrF4eNXyUjFi5-p_RCY65f2Uq13458Nj2spZNgQ#targetpop" } ], "https://w3id.org/neurodkg/indicationType": [ { "@id": "https://w3id.org/neurodkg/AdjunctiveTherapy" } ] }, { "@id": "http://purl.org/np/RAZW8rLrF4eNXyUjFi5-p_RCY65f2Uq13458Nj2spZNgQ#quote", "http://www.w3.org/ns/prov#value": [ { "@value": "Vigabatrin for oral solution is indicated as adjunctive therapy for adults and pediatric patients 2 years of age and older with refractory complex partial seizures who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss" } ], "http://www.w3.org/ns/prov#wasQuotedFrom": [ { "@id": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b8fb137-848b-45fd-9107-a6db5a675360" } ] } ] }, { "@id": "http://purl.org/np/RAZW8rLrF4eNXyUjFi5-p_RCY65f2Uq13458Nj2spZNgQ#pubinfo", "@graph": [ { "@id": "http://purl.org/np/RAZW8rLrF4eNXyUjFi5-p_RCY65f2Uq13458Nj2spZNgQ#sig", "http://purl.org/nanopub/x/hasAlgorithm": [ { "@value": "RSA" } ], "http://purl.org/nanopub/x/hasPublicKey": [ { "@value": "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCC0CnI6yMUipkXh7RB8b/9rRnO8+qDR+pJVf//jGV0r2nd7JcvWFkhPN/eLja/pUw/+nvTE24rhKqK/jWxppJLoka+bk57wrYw43DrSbzQWoJc3ImWe3d08jSYt3mh3uOLWKciogBaonJUBohJsqhTmOULevIPONTZOMzeOJTWwQIDAQAB" } ], "http://purl.org/nanopub/x/hasSignature": [ { "@value": "SMoY3+Pw5txXR4ZS30apawCoROuFB2DscfnJCZWppVJj1jABDMESHkL56KkWUy5p5t4NfcWw1WKgRbv6KiQzlvtMt5962ewi0iVtCOqiHT/2yctQJiE5IFFkEfj8WifovUpOCFjSHKYBD+MucC7WkAmbuiGW60pmp6Dp/s6QRo8=" } ], "http://purl.org/nanopub/x/hasSignatureTarget": [ { "@id": "http://purl.org/np/RAZW8rLrF4eNXyUjFi5-p_RCY65f2Uq13458Nj2spZNgQ" } ] }, { "@id": "http://purl.org/np/RAZW8rLrF4eNXyUjFi5-p_RCY65f2Uq13458Nj2spZNgQ", "http://purl.org/dc/terms/created": [ { "@value": "2021-04-04T21:36:27.877+02:00", "@type": "http://www.w3.org/2001/XMLSchema#dateTime" } ], "http://purl.org/dc/terms/creator": [ { "@id": "https://orcid.org/0000-0003-4665-7473" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate": [ { "@id": "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate": [ { "@id": "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate": [ { "@id": "http://purl.org/np/RA64ptuigOfVGfIhpdwWeJnssaHV9jTQCnAm6Pvgrvmos" } ] } ] }, { "@id": "http://purl.org/np/RAZW8rLrF4eNXyUjFi5-p_RCY65f2Uq13458Nj2spZNgQ#provenance", "@graph": [ { "@id": "http://purl.org/np/RAZW8rLrF4eNXyUjFi5-p_RCY65f2Uq13458Nj2spZNgQ#assertion", "http://www.w3.org/ns/prov#wasAttributedTo": [ { "@id": "https://orcid.org/0000-0003-4665-7473" } ] } ] } ]